infographic feature

Better together? biosimilars sector says aye

By Gareth Macdonald and Dan Stanton

- Last updated on GMT

Related tags: Biogen idec, Rituximab, Us

Bright eyes was OK at best
Bright eyes was OK at best
Partnerships are a mixed bag.For every oppressed group yearning to throw off the yoke of their imperialist overlords, there is an Art Garfunkel or Daryl Hall solo album to illustrate the positive impact collaboration can have.

For the biopharmaceutical industry partnering is a well-established practice.

The development and commercialisation of the autoimmune disorder mAb Rituximab, for example, involves Biogen Idec, Roche subsidiary Genentech, Chugai and Zenyaku in Japan and AryoGen in Iran.

Similarly, when drug industry group Transcelerate Biopharma​ was established in 2012 the idea was to foster greater collaboration between drug developers on the basis that more efficient R&D was good for the sector as a whole.

Celltrion top dealmaker

It is little wonder then that biosimilars firms hoping to tap into the market created by biopharma innovation use similar tactics. The infographic below illustrates the extent of partnering in the biosimilars space.

Leading the field, at least in terms of the number of collaborations, is South Korea’s Celltrion.

The firm, which filed its first biosimilar with the US FDA last month​, has previously established development alliances with, amon others, Hospira​, Egis​, Hikma​, Perrigo​, Nippon Kayaku, BioGaran​ (Korean) and Mundipharma​.

Celltrion is closely followed by Merck & Co, which has biosimilar-related deals with Hanwa, Samsung Bioepsis, and Fujifilm among others, with Baxter, Samsung Biologics and Actavis next on the list in terms of number of agreements.

Whether this partnering, and presumably risk sharing, approach to development will work for the biosimilars sector remains to be seen. But what is clear is that a few key firms are likely to benefit more than most if and when the market does take off.

And Biopharma-Reporter will be delving deeper into the issues affecting biosimilars with a free virtual event on September 26. Join four industry experts as they discuss the development, manufacture and sale of such products in a 60 minute seminar hosted by our Editor-in-Chief Gareth Macdonald. Click here​ for more details... 

Related news

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more